Abstract: Embodiments of the disclosure provide a circuit, chip, system, and method for eliminating random perturbation. The circuit includes a weight calculating module for receiving digital signals and random perturbation digital quantity, using least mean square error algorithm to calculate weight deviation iteration coefficient based on digital signal and digital quantity, and updating perturbation weight in real-time according to weight deviation iteration coefficient; and a perturbation eliminating module for eliminating perturbation signal in output digital signal of quantizer according to perturbation weight updated in real-time and updating perturbation weight in real-time according to weight deviation iteration coefficient, and then calculating current perturbation weight in real time to realize self-calibration of perturbation weight.

Abstract: A spinning solution, a heat-resistant creep-resistant fiber and preparation method therefor are provided. The spinning solution includes a polyethylene, a solvent and a photoinitiator, and the content of the photoinitiator is 0.2 wt %-10 wt % of the mass of the polyethylene; gel-spinning and multi-stage drafting the spinning solution; then performing ultraviolet irradiation by an ultraviolet light source to obtain a heat-resistant creep-resistant polyethylene fiber; the light intensity and the time of the ultraviolet light source is 100 W/cm2-5000 W/cm2 and 10 s-600 s, respectively; the gel content and the crystallinity of the heat-resistant creep-resistant polyethylene fiber is 20 wt %-100 wt % and 50 wt %-90 wt %, respectively; the creep rate of the fiber is 10?8 s?1-10?7 s?1 under conditions of a temperature of 70° C. and a load of 300 MPa; the fracture temperature of the fiber is 155° C.-245° C. under conditions of a load of 15 MPa and a heating rate of 2° C./min.

Abstract: An interface circuit and an electronic apparatus, including: a programmable current array (1), generating a first current and a second current transmitted to a common mode and differential mode generation circuit (2) according to an input code, and a third current and a fourth current transmitted to a driving bias generation circuit (3) according to the input code; the common mode and differential mode generation circuit (2), generating a common mode voltage according to the first current, and generating a high level voltage and a low level voltage according to the second current and the common mode voltage; a driving bias generation circuit (3), simulating a load according to the third and fourth currents, and generating a bias voltage based on the load and the low and high level voltages; an output driving circuit (4), converting an input signal into a differential signal in which the common mode voltage and a differential mode amplitude are configurable.

Abstract: Examples of the present disclosure describe systems and methods for generating multiple semantic hypotheses for search query intent understanding. In aspects, a search query may be received by a query analysis component associated with a search system. The query analysis component may be used to evaluate the search query for ambiguity in the domain, intent, and/or slot(s) of the search query. A set of hypotheses representing for one or more combinations of the domain, intent, and/or slot(s) of the search query may be generated. The set of hypotheses may be scored and/or ranked. Based on the scores/ranks, one or more of the hypotheses in the set of hypotheses may be provided to a user and/or one or more processing components accessible to the search system.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: The present disclosure proposes a modeling method and apparatus for diagnosing an ophthalmic disease based on artificial intelligence, and a storage medium. The modeling method includes: establishing a data collection of ophthalmic images and a data collection of non-image ophthalmic disease diagnosis questionnaires; training a first neural network model by employing the data collection of the ophthalmic images to obtain a first classification model; training a second classification model by employing the data collection of non-image ophthalmic disease diagnosis questionnaires; and merging the first classification model and the second classification model to obtain a target classification network model, in which, a test result outputted by the target classification network model is used as a diagnosis result of the ophthalmic disease.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: Examples of the present disclosure describe systems and methods for enterprise search that leverage periodically updated user context of an enterprise user for intent understanding and treat a search session as a dialog between the user and a digital assistant to allow multi-modal interaction. For example, a query input by the user may be received from a client application having search functionality and an integrated assistant. A current state of the user context may be leveraged to understand the query. Based on the understanding, one or more responsive entities may be retrieved from an enterprise search index as results. Based on the results, a response may be generated that includes the results and a prompt to cause the user to further refine the query and/or provide feedback. The response may be provided to the client application for output as part of a search session dialog between the user and assistant.

Abstract: Examples of the present disclosure describe systems and methods for generating multiple semantic hypotheses for search query intent understanding. In aspects, a search query may be received by a query analysis component associated with a search system. The query analysis component may be used to evaluate the search query for ambiguity in the domain, intent, and/or slot(s) of the search query. A set of hypotheses representing for one or more combinations of the domain, intent, and/or slot(s) of the search query may be generated. The set of hypotheses may be scored and/or ranked. Based on the scores/ranks, one or more of the hypotheses in the set of hypotheses may be provided to a user and/or one or more processing components accessible to the search system.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: A method, an apparatus and a system for information retrieval are provided. The method for information retrieval may comprise: receiving a query in a natural language form from a user (210); extracting a plurality of feature vectors from the query based on a plurality of knowledge entries in a knowledge base associated with the user and a built-in featurization source, one feature vector per knowledge entry (220); obtaining, with a pre-trained language understanding model, a plurality of language understanding results based on the plurality of feature vectors (230); and selecting a knowledge entry corresponding to the query among the plurality of entries based on the plurality of language understanding results (240). The method may extract more features and combine information retrieval and language understanding in one shot to improve efficiency.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: The present disclosure proposes a modeling method and apparatus for diagnosing an ophthalmic disease based on artificial intelligence, and a storage medium. The modeling method includes: establishing a data collection of ophthalmic images and a data collection of non-image ophthalmic disease diagnosis questionnaires; training a first neural network model by employing the data collection of the ophthalmic images to obtain a first classification model; training a second classification model by employing the data collection of non-image ophthalmic disease diagnosis questionnaires; and merging the first classification model and the second classification model to obtain a target classification network model, in which, a test result outputted by the target classification network model is used as a diagnosis result of the ophthalmic disease.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.